Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.…
Vicore Pharma to Participate in the DNB Carnegie Nordic Healthcare Conference
Vicore Pharma Holding (NASDAQ: VCRE) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 50 employees.
The shares were at 9.405 USD on 20 November 2026. Its 52-week range is 8.390 USD to 17.80 USD: the price is 47.2% below the high and 12.1% above the low.
Its market capitalisation is 264.89M USD.
Vicore Pharma Holding reports return on equity of -43.6%, an operating margin of 0.0% and revenue down 21.8% year over year.
Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 24.35 USD is 158.9% above the current price.
No upcoming events tracked.